On August 14, 2026, Werewolf Therapeutics sold its pre-clinical INDUCER and INDUKINE platforms to EMD Serono Research & Development Institute Inc. for $33 million in upfront cash consideration. The company retains rights to develop WTX-124 and WTX-330 under an exclusive license from EMD. Werewolf Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.
